Chemotherapy has been implicated in causing CRCI, with terms such as “chemobrain” or “chemofog” often used to refer to this syndrome (7, 20–23). The cognitive domains affected in chemotherapy-associated CRCI include learning, memory, attention, executive function, language and processing speed (2, 8). In longitudinal studies, the incidence of CRCI after chemotherapy is reported from 17% to over 70% among cancer patients (2). Known risk factors that increase incidence of CRCI after chemotherapy include non-cancer related comorbidities, anemia, and genetic predisposition (24, 25). The proposed mechanisms for chemotherapy-associated CRCI include decreased neurogenesis, axonal degeneration and demyelination, reduction in dendrite volume and length, increased oxidative stress and free radical formation, neuroinflammation, toxicity to CNS progenitor cells, microglia apoptosis, blood brain barrier disruption, brain blood flow alterations, myelin degradation, production of damage associated molecular patterns, cytokine-induced neurotoxicity, reduced glucose metabolism, alteration in brain water content, and fluctuations in neurotransmitter levels (5, 14, 22, 23, 25, 26). Select chemotherapy drugs, including 5-fluorouracil (5-FU), carmustine (BCNU), lomustine (CCNU), temozolomide (TMZ) cross the intact blood brain barrier to directly injure the brain. Additional drugs such as methotrexate (MTX), paclitaxel, docetaxel (DTX), cisplatin may cross in small concentrations to negatively affect brain tissue (11, 22, 25–27). However, for drugs like doxorubicin (DOX), known to be associated with CRCI, it is unclear how it alters neural cells. Chemotherapy-associated CRCI is often mild to moderate in severity and can be dependent on the chemotherapy agent received and the dose (2, 8, 28). Chemotherapy agents such as MTX, BCNU, fludarabine, cytarabine and 5-FU can cause severe neuropathological diseases including encephalopathy and dementia (2).

The bulk of our understanding of chemotherapy-associated CRCI stems from studies of cognitive impairment in BC survivors during and after chemotherapy treatment (summarized in Table 1 ) (19, 29, 64, 80–82). BC patients after chemotherapy treatment report deficits in cognitive domains consisting of executive function, working memory, attention, concentration, processing speed, cognitive flexibility, visual and verbal memory (83). Various structural brain changes have been described in these BC patients, including reduction in gray matter, decreases in white matter integrity, altered brain activation, neuroinflammation and changes in brain functional connectivity (4, 8, 15, 18, 28, 84–86). PET imaging acquired 5-10 years after treatment in BC patients demonstrated altered frontal cortex activation during a short term verbal memory task in survivors treated with chemotherapy compared to survivors not treated with chemotherapy (84). One study used PET-MR imaging and neuropsychological testing to demonstrate that compared to patients treated with surgery alone, BC patients treated with surgery and adjuvant chemotherapy had higher brain local translocator protein expression, a measure of neuroinflammation that was associated with worse cognitive performance (4).

Mechanistically, numerous studies have implicated systemic inflammation as a major contributor to chemotherapy-associated CRCI in BC patients. Chemotherapy associated inflammation is a potential significant contributor to CRCI; a thorough review of this subject is beyond the scope of the paper but has been well described in recent years (15, 80, 81). Chemotherapy agents have been reported to elevate multiple pro-inflammatory markers including interlukin-6 (IL-6), IL-1 beta (IL-1β), IL-5, IL-10, reactive oxygen species (ROS), IL-8, interferon gamma (IFN-α), IL-12, IL-17, and tumor necrosis factor alpha (TNF-α) (15, 82). Cognitive performance in chemotherapy-treated BC patients have specifically been linked to serum inflammatory markers (11, 29, 30, 64). One study found an association between increased concentrations of soluble tumor necrosis factor receptor I and II and decline in visual memory (29). Another study demonstrated a significant interaction between serum IL-6, TNF-α levels and verbal memory difficulties in BC patients treated with chemotherapy (64). In BC patients, one study showed that higher elevations in IL-6 and IL-1β were associated with more severe cognitive impairment (31) These studies support that select chemotherapy agents increase circulating inflammatory markers which subsequently cross the blood brain barrier to activate microglia and induce neuronal cell death (23, 87).

Several CRCI studies have evaluated the long-term impact of the adjuvant chemotherapy protocol CMF that includes cyclophosphamide (CYP), MTX and 5-FU for early-stage breast carcinoma (32). One study evaluated cognitive impairment via neuropsychological testing and self-reporting in BC patients 21 years following adjuvant CMF chemotherapy (65). These survivors performed worse on cognitive tests of learning, verbal memory, information processing speed, inhibition and psychomotor speed compared to non-cancer-bearing women (65). BC survivors also reported memory complaints that were not associated with neuropsychological testing, a commonly reported phenomena in other studies (20, 32, 33, 65). One study compared cognitive impairment at 2 years in BC survivors treated with surgery and adjuvant CMF and age-matched BC survivors treated with surgery only (32). In this study, CMF-treated survivors reported significantly more difficulties with memory and concentration and increased incidence of cognitive impairment than BC patients treated with surgery alone (32). An additional study evaluated stage I and II breast carcinoma patients 3-18 months after CMF treatment and found that 75% of patients scored 2 standard deviations below test norms (corrected for age, education and gender) on one or more neuropsychological tests (34). Another study showed that BC survivors treated with CMF at least 10 years prior had significant impairment in cognitive domains of executive function, working memory and divided attention compared to age, education status matched non-cancer controls (66). The underlying mechanisms leading to altered cognition are not clear. However, one study showed that 20 years after adjuvant CMF treatment, BC survivors had increased levels of systemic inflammation (increased granulocyte count to lymphocyte count ratio (GLR), increased platelet count to lymphocyte count ratio and increased platelet count times GLR) and lower cognitive performance compared to healthy controls (67).

While CMF-treated BC patients have provided abundant information regarding this syndrome, CRCI has also been documented and evaluated following administration of many adjuvant chemotherapy protocols. Chemotherapy-treated BC patients (most of whom received 5-FU, DOX and CYP) in one study were more likely to show cognitive impairment on neurophysiological tests than healthy women controls (21). In another study, BC survivors treated with a wide variety of multi-agent treatment protocols incorporating DOX, CYP, DTX, paclitaxel, MTX, 5-FU or epirubicin, demonstrated deficits in episodic memory as compared to age- and sex-matched non-cancer controls 6 months following treatment (20). One-to-two years following treatment with either DOX and CYP or CYP, epirubicin and 5-FU, significantly more BC survivors demonstrated moderate to severe cognitive impairment compared to age, sex, and educational status matched non-cancer controls (35). A recent prospective study showed that BC patients treated with a diverse repertoire of multi-agent chemotherapy protocols were at a threefold greater risk of cognitive decline compared to BC patients treated with hormone therapy (36). Notably, a prospective study showed that cognitive impairment in chemotherapy-treated BC patients was worse in the presence of anxious or depressive symptoms (30).

Chemotherapy-induced CRCI has been demonstrated in other malignancies ( Table 1 ), including hematopoietic malignancies and testicular cancer (TC) (37, 38, 40, 41, 43, 68). Cancer survivors, including patients treated for non-Hodgkin’s and Hodgkin’s lymphoma, have cognitive impairment in domains including memory, learning and executive function for at least 6 months following chemotherapy compared to healthy controls (41, 42, 44). Twenty percent of TC patients report worsening cognitive impairment 2 years following multiagent bleomycin, etoposide and cisplatin (BEP) therapy using quality-of-life questionnaires (37, 69). Interestingly, TC patients treated with BEP did not have significant cognitive differences on neuropsychological testing from TC patients treated with radiation therapy and surgery (69, 70, 74, 75). BEP therapy has also been shown to cause significant brain networking changes and altered white matter microstructure in TC patients for durations up to 14 years after treatment compared to TC patients who did not receive chemotherapy (39, 73). Additional studies of TC survivors with long-term follow up for at least 2 years post treatment have found cognitive impairment following multiagent chemotherapy with or without ECRT compared to survivors treated with surgery alone (71, 72).

Extracranial radiation therapy (ECRT) is associated with cognitive impairment in cancer patients. There are substantial health implications of this phenomenon because over 50% of all newly diagnosed cancer patients will receive ECRT as part of their treatment protocol (7). Importantly, radiotherapy is prescribed in an estimated 56% of breast and prostate cancer patients (88, 89). Unsurprisingly, brain irradiation for primary or metastatic tumors causes brain damage leading to neurocognitive decline (5, 6). Somewhat less intuitively, cognitive impairment has been associated with ECRT directed to tumor-bearing anatomic sites outside the brain (5, 7, 45, 46). Little is known regarding the potential mechanism(s) linking ECRT and CRCI.

Similar to chemotherapy-associated CRCI, clinical evidence for ECRT-associated CRCI has arisen from BC survivors ( Table 1 ). Studies have shown impairment in multiple cognitive domains in BC survivors after ECRT including complex cognition, attention, memory, and executive function (7, 20, 23). One study showed that 6 months following surgery and ECRT (no chemotherapy), BC survivors demonstrated higher rates of impairment in attention compared to age matched non-cancer control women (20). A separate study that assessed cognitive function via neuropsychological tests and self-reporting showed that 6 months after treatment, BC patients treated with ECRT only or chemotherapy and ECRT (chemoRT) had similar prevalence of cognitive impairment (47). This cognitive dysfunction is robust and lasts years following ECRT. BC patients treated with ECRT only or chemoRT sustained cognitive impairment at 1 year post ECRT (45). An additional longitudinal study found that BC patients treated with ECRT or chemoRT demonstrated worse cognitive performance compared to age matched non-cancer-bearing women in areas of executive function and processing speed up to 3 years post treatment (76). Similar to chemotherapy-induced CRCI, cognitive dysfunction has been documented in patients treated with ECRT for a variety of solid and hematologic tumor types (48). Moreover, this broad study supported that the impact of treatment extends well beyond resolution of acute radiation toxicities, as cancer patients treated with chemotherapy, ECRT or chemoRT reported problems with memory and concentration up to 6 months post treatment (48). ECRT-induced CRCI has also been documented in TC survivors (69, 71). Indeed, in one study with follow-up of TC survivors for over 20 years post treatment documented cognitive impairment with ECRT compared to age matched healthy controls (75).Similar to the proposed mechanisms underlying the contribution of chemotherapy to CRCI, it has been hypothesized that ECRT exerts its bystander cognitive impact through the circulatory trafficking of ECRT-induced pro-inflammatory cytokines to the brain that subsequently induce cognitive impairment (23, 46, 90, 91). Pro-inflammatory cytokines that are produced after ECRT include IL-1β, IL-1α, TNF-α, IL-6, IL-4, INF-ϒ, IL-8 (91, 92). IL-6 has been implicated as a potential cytokine target, as one study demonstrated memory deficits identified in BC patients up to 7 months post-ECRT were partially mediated by elevated plasma IL-6 levels (46).

Chemotherapy and ECRT have garnered abundant attention as critical treatment modalities linked to CRCI. However, deleterious cognitive effects are reported with a diagnosis of cancer as well as with almost all cancer treatments, including surgery, endocrine therapy and immunotherapy ( Table 1 ) (2, 93). Alarmingly, studies estimate that 40% of BC patients exhibit CRCI before the start of therapy; this may therefore be exacerbated with treatment (2). Early identification of patients at risk for CRCI, as well as knowledge of signals that contribute to CRCI, may aid in development of both preventive and mitigative strategies.

Endocrine therapy can cause cognitive impairment in cancer patients and appears to predominately affect the domains of verbal memory and processing speeds (2, 8, 94). Specific drugs associated with CRCI include aromatase inhibitors, selective estrogen receptor modulators/agonists and androgen deprivation therapy (8, 49, 77, 94, 95). The proposed mechanisms by which endocrine therapies cause CRCI are reduction in brain N-methy-D-aspartate receptor concentration, down regulation of brain derived neurotrophic factor expression, decreased antioxidant capacity of cells in the brain, and decreased amyloid β clearance (94). Use of tamoxifen, a commonly prescribed and important adjuvant therapy for women with hormone receptor positive BC, has been correlated with a reduction on measures of memory, verbal fluency, visuospatial functioning and processing speed (2, 77). In one study, women taking tamoxifen were more than twice as likely to report seeing a physician for memory issues as compared to BC patients not taking tamoxifen (96). Another study found that adjuvant hormonal therapy in BC patients has been associated with decreased verbal memory and processing speed (95). Tamoxifen may be given following chemotherapy or concurrent with chemotherapy, which may confound the effects of each individual drug. However, tamoxifen appears to play an important role in mediating CRCI as BC patients treated with tamoxifen and chemotherapy in one study had increased declines in visual memory and verbal working memory versus patients treated with chemotherapy alone (50). Prostate cancer patients treated with androgen deprivation therapies, including abiraterone acetate and enzalutamide, also report cognitive impairment (49, 94). One study found that patients with metastatic prostate cancer treated with enzalutamide had a significantly higher risk of clinically meaningful and worsening cognitive impairment than patients treated with abiraterone acetate plus prednisone up to 3 months after therapy (49).

Immunotherapies including cytokines, checkpoint inhibitors, chimeric antigen receptor (CAR) T cell therapies and hematopoietic stem cell transplantation have also been associated with CRCI (43, 51, 58, 59, 62, 94, 97). One study in patients with chronic myelogenous leukemia treated with interferon-alpha (INF-α) (with or without chemotherapy) showed declines in information processing and executive function when assessed by neuropsychological testing (51). This study also showed that 50% of the patients had significant declines in performance on one or more neuropsychological tests (51). Patients with melanoma, small cell lung cancer, non-small cell lung cancer and Merkel-cell carcinoma have exhibited neurotoxicity following immune checkpoint inhibitors five weeks after treatment (98). Approximately one-third of cancer patients had neurocognitive impairment after treatment with the popular immune checkpoint inhibitor pembrolizumab (52). Similar findings were found in a cross-sectional study, in which 41% of cancer survivors treated with the checkpoint inhibitor ipilimumab, had deficits in working memory and verbal memory (53). Cognitive impairment extends to CAR T-cell therapy as well, with 36% of 84 lymphoma patients treated with a CD19-targeted CAR T-cell developed severe cognitive impairment after treatment (54, 55). Up to 37% of patients with hematological neoplasms treated with CD-19 targeted CAR T-cell therapy reported cognitive impairment in one or more cognitive domains including memory, language, attention, and executive functioning, even up to 90 days after treatment (55, 56). Following allogeneic hematopoietic stem cell transplant for treatment of hematopoietic neoplasia, patients may demonstrate decline in verbal learning, reaction time, working memory, learning, executive function, attention, and psychomotor speed assessed by neuropsychological testing (58, 60, 61, 63, 78). In one study, up to 38% of patients with hematopoietic neoplasia had at least mild cognitive impairment 5 years following allogeneic bone marrow transplant (79). A separate study suggested that 41% of patients with hematopoietic neoplasia showed impairment in at least 1 cognitive domain one year post allogeneic bone marrow transplant (62).

Immunotherapies may contribute to CRCI via microglia-mediated neuronal death secondary to the production, circulation, and blood brain barrier penetration of proinflammatory cytokines (94). This supposition is supported by one study of non-CNS cancer patients demonstrating cognitive impairment that was correlated with pro-inflammatory plasma biomarkers including interferon-gamma (INF-ϒ), interleukin one beta (IL-1β), interleukin two (IL-2) and fibroblast growth factor two (FGF2) (57).

Clinical studies demonstrate serious cognitive impairment in cancer survivors that impacts quality-of-life measures for years following local and systemic treatments. Several treatments have been linked to changes in the brains of cancer patients, and to pro-inflammatory biomarkers in circulation. Future studies to identify reliable biomarkers may prove beneficial for detection, monitoring and response to treatment strategies aimed at preventing or mitigating CRCI.

Rodent studies have characterized the scope and mechanistic underpinnings of the cognitive impact of cancer treatments in both tumor-bearing and non-tumor bearing rodents. This has included studies of chemotherapy (single or multi-agent), ECRT, surgery, hormonal therapy and immunotherapy (5, 23, 26, 87, 93, 102, 103). Within the chemotherapy space, rodent studies have evaluated the effects of intravenous or intraperitoneal administration of alkylating agents (CYP, temozolomide, thiotepa), platinums (cisplatin, oxaliplatin, carboplatin), antimetabolites (MTX, 5-FU, cytosine arabinoside, cytarabine), anthracycline (DOX, epirubicin), antimicrotubule agents (vincristine, paclitaxel, DTX), cytosine arabinoside (cytarabine) and topoisomerase I inhibitor (topotecan) (5, 23, 26, 87, 99). Rodent studies investigating the mechanisms of ECRT induced CRCI, include ECRT models of non-CNS cancer treatment (5, 7, 12, 102). In this model, ECRT is represented by a single dose of ECRT to an extracranial region, such as the skin of the hindlimb, in tumor-free or tumor-bearing animals (5, 7, 12, 102).

Behavioral testing in rodents ( Table 2 ) has bolstered the findings of long-lasting, potentially severe cognitive deficits following chemotherapy from observational studies of human cancer patients (15). Importantly, behavioral tests used in rodent CRCI studies evaluate similar cognitive domains as those reported to be affected in human CRCI studies, maximizing translational strength of these models. Testing in rodents evaluates memory, learning, executive function, attention and cognitive flexibility (5, 26, 99). In exploring the impact of chemotherapy on cognition in rodents, researchers have evaluated a wide variety of chemotherapy regimens in both tumor-free and tumor-bearing animals (23, 26). This work has revealed deficits in spatial working memory in rodents treated with cisplatin, vincristine, CYP, DOX, BCNU, topotecan MTX + 5-FU, CYP + DOX or CYP + DOX + 5-FU (99, 104–111, 152). Additionally, recognition/visual memory was reduced in rodents following single agent administration of cisplatin, DOX, MTX, 5-FU, CYP, DTX, thiotepa and oxaliplatin (OXP) (5, 100, 112–122). Multi-agent chemotherapy including CYP + DOX and OXP + 5-FU also resulted in impaired recognition/visual memory (123–127). Rodent learning was diminished after administration of several single and multiagent protocols, including cisplatin, BCNU, MTX, CYP, DOX, OXP, TMZ, MTX + 5-FU, CYP + DOX (128–138). Rodents have decreased executive function after treatment with the following chemotherapy agents MTX, 5-FU, cytarabine, and MTX + 5-FU (139–143). Some chemotherapy agents including carboplatin, DTX, CYP and topotecan also increase attention deficits (99, 144). Finally, cognitive flexibility appears to be impaired in rodents treated with 5-FU, MTX + cytarabine, paclitaxel and cisplatin (139, 145–148). Collectively, the broad and significant negative impact that systemic chemotherapy has on cognitive function in rodent models mirrors cognitive impairment described in pediatric and adult cancer patients.

The impact of ECRT on cognition has been less thoroughly explored in rodent models but is of recent interest. Most notably, one study demonstrated that hippocampal dependent memory was impaired in mice treated with ECRT as compared to untreated control mice (5). Importantly, the memory deficits in these mice were comparable to mice treated with DOX and DOX + ECRT (5). The results of this study complement those reported in a carcinoma-bearing mouse model in which combination immunotherapy and ECRT lead to impairment in visual/recognition memory as compared to non-treated, tumor free control mice (102).

Hormonal therapy in intact rodents has also been shown to negatively impact memory, learning and executive functioning (103, 141). One study found that tumor-free mice treated with tamoxifen, MTX and/or 5-FU had compromised learning and executive function as compared to untreated control mice (141). This work parallels other studies that have shown that tamoxifen alone can cause impairment in memory, learning and executive function (149–151). Finally, surgical anesthesia has been shown to induce deficits in working memory and recognition/visual memory (93). A study reported that rats anesthetized with sevoflurane inhalant demonstrate diminished working and recognition memory as compared to untreated control rats (93).

While the descriptive confirmation of the impact of cancer treatment on the development of CRCI has been well documented in rodent models, studies have also provided invaluable insights into the mechanistic links between treatment and CRCI. Such work has shown that cancer treatments result in reduced neurogenesis, neuroinflammation, reduced brain glucose metabolism, alterations in brain neurotransmitter levels, decreased brain myelination, detrimental changes in neuron axons and dendrites, increased cellular damage in the hippocampus, reduction of white matter integrity, DNA damage, oxidative stress and mitochondrial dysfunction in the hippocampus (26, 121, 134, 148).

Multiple studies have positively correlated the behavioral deficits observed in treated mice to pathological changes within the brain (106, 142). One study demonstrated a positive correlation between DNA damage in the brain cells of mice treated with 5-FU and the learning deficit seen in these mice (142). Another study found in rats treated with 5-FU and methotrexate a significant correlation between decreased neurogenesis in the hippocampus of these rats and impairment of hippocampal memory (106). Similar associations have been found in BC patients treated with chemotherapy (4).

The impact of single-agent and multi-agent chemotherapy on neurogenesis, particularly within the hippocampus, is well-documented (26, 87, 153). Specifically, 14 independent rodent studies have shown that treatment with BCNU, MTX, 5-FU, CYP, DOX, TMZ, cisplatin, thiotepa, DOX + CYP, MTX+5-FU and CYP + DOX + 5-FU results in decreased neurogenesis in the hippocampal dentate gyrus as compared to non-chemotherapy treated rodents (100, 106, 111, 112, 122, 124, 129, 132, 135, 145, 148, 154–156). One study in rats expanded upon these findings and demonstrated that treatment with MTX+5-FU resulted in detectable cognitive dysfunction that correlated with reduced hippocampal neurogenesis (106). It is not yet clear how systemic chemotherapy impacts neurogenesis. Decreased levels of hippocampal brain-derived neurotropic factor and doublecortin may disrupt neurogenesis, based on one study in rats following 5-FU administration (116). Reduced neurogenesis following chemotherapy is one of several potential mechanisms by which chemotherapy alters cognition. This occurrence has profound implications in human patients because reduced neurogenesis may also contribute to depression and accelerate cognitive diseases like Alzheimer’s (157).

There is also robust evidence that cancer treatments induce neuroinflammation, which can lead to cognitive dysfunction itself while also contributing to reduced neurogenesis. Numerous studies have documented neuroinflammation or upregulation of brain proinflammatory cytokines, or both in rodents treated with chemotherapy, ECRT, immunotherapy or combination therapy (5, 100, 158). Specific chemotherapy agents that cause neuroinflammation in rodents include CYP, DOX and MTX (100, 133, 159). Two recent murine studies have also shown that hindlimb irradiation with appropriate blocking of CNS tissue, results in widespread brain astrocytosis and microgliosis (components of neuroinflammation) up to 30 days after ECRT treatment compared to control mice (5, 7). A similar finding was described in both tumor-free and tumor-bearing mice treated with immunotherapy or hindlimb irradiation or both had increased activated microglia in the hippocampus and cortex as compared to untreated control mice (102). These studies are complemented by work documenting increased levels of pro-inflammatory reactive oxygen species (ROS) in rodent models of CRCI. Cancer treatments in rodents increase ROS characterized by increased oxidative stress and DNA damage (87). The chemotherapy agents cisplatin, carboplatin, CYP, BCNU, cytarabine, DOX, and MTX have specifically been shown to increase brain oxidative stress (138, 160–168). Of import to cancer patients undergoing surgical procedures, the anesthetic agent sevoflurane has also been shown to cause increased hippocampal oxidative stress in rats (93).

Metabolic derangement has been highlighted in other studies as an important potential contributing factor to CRCI. Decreased brain glucose metabolism has been observed during FDG (fluorodeoxyglucose)-PET scan in rodents treated with either chemotherapy or ECRT (7, 136, 159, 169). Rats treated with CYP or DOX in one study showed decreased glucose metabolism in the medial cortex with both treatments and in the hippocampus in the DOX-treated rats (136). Similar findings were seen in a study in which DOX-treated rats had decreased prefrontal cortical glucose metabolism 30 days post treatment compared to untreated controls (169). MTX treatment to rats also caused reduced hippocampal glucose metabolism with decreased blood vessel density compared to untreated rats (159). Mice treated with hindlimb irradiation alone also developed reduced brain glucose metabolism after treatment compared to their pre-ECRT brain imaging (7).

Alterations in neurotransmitter levels and neurotransmission has been shown in the brains of rodents treated with MTX, 5-FU, carboplatin and DOX (6, 130, 144, 170, 171). Decreased levels of hippocampal norepinephrine, dopamine and serotonin were measured following MTX administration (130). Additionally, impaired dopamine release and update occurred following carboplatin and 5-FU administration in rats (144, 170). In mice, treatment with DOX results in impaired glutamatergic signaling (171). Finally, changes in the structures of rodent neuronal dendrites and axons have been described after chemotherapy (26, 121). Specifically, CYP, cisplatin and cytarabine have shown to reduce dendritic length, volume, spine density and number of branch points (26, 100, 117, 172). Cisplatin given to rats has also resulted in reduced hippocampal pyramidal neuron dendritic branching and spine density up to 28 days after administration (121).

Collectively, animal studies have demonstrated impairment in cognitive domains similar to cancer survivors after systemic and local antineoplastic treatment. Cognitive impairment has been correlated to neuropathological findings in the brain of rodents, which has led to the identification of potential mechanisms of cancer therapy-induced CRCI. Mechanisms implicated in the cause of CRCI include decreased neurotransmission, disruption of the blood brain barrier, impaired neurogenesis, increased neuronal oxidative stress, neuroinflammation, and decreased cerebral blood flow (87). Decreased neurotransmission is thought to be due to pro-inflammatory cytokines such as IL-1β that can lead to the catabolism of neurotransmitters and dysregulation of neurotransmission that can cause cognitive impairment (13, 87). Disruption of the blood brain barrier via peripheral cytokine dysregulation can lead to neuroinflammation causing cognitive impairment (13). Rodent animal models have highlighted that cancer treatments decreases neurogenesis through the production of pro-inflammatory cytokines such as TNF-α and subsequent activation of glial cells (22, 87, 94). Most cancer treatments induce the production of reactive oxygen species and oxidative stress, which in turn leads to neuronal DNA damage (22, 87, 91, 94). Pro-inflammatory cytokines produced in the tumor microenvironment can enter circulation and cross the blood brain barrier, leading to the activation of glial cells (13). Activated glial cells contribute to neuron damage and cognitive impairment (6, 173). Finally, several preclinical models have shown that cancer treatment can reduce cerebral blood flow and glucose metabolism, further contributing to cognitive impairment (7, 87, 94, 174). Importantly, most of the proposed mechanisms include a significant initial contribution from pro-inflammatory mediators. Further work in animal models is needed to target these pro-inflammatory mediators in attempts to elucidate new approaches that may mitigate CRCI.